These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 11297418)

  • 1. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
    Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
    Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation.
    Qin Z; Hu D; Zhu M; Fink AL
    Biochemistry; 2007 Mar; 46(11):3521-31. PubMed ID: 17315948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model for amyloid fibril formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding.
    Khurana R; Souillac PO; Coats AC; Minert L; Ionescu-Zanetti C; Carter SA; Solomon A; Fink AL
    Amyloid; 2003 Jun; 10(2):97-109. PubMed ID: 12964417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors.
    Hora M; Sarkar R; Morris V; Xue K; Prade E; Harding E; Buchner J; Reif B
    PLoS One; 2017; 12(7):e0181799. PubMed ID: 28746363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation.
    Kim YS; Randolph TW; Manning MC; Stevens FJ; Carpenter JF
    J Biol Chem; 2003 Mar; 278(12):10842-50. PubMed ID: 12529361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of amyloid fibrils in vitro from partially unfolded intermediates of human gammaC-crystallin.
    Wang Y; Petty S; Trojanowski A; Knee K; Goulet D; Mukerji I; King J
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):672-8. PubMed ID: 19684009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dependence on solution conditions of aggregation and amyloid formation by an SH3 domain.
    Zurdo J; Guijarro JI; Jiménez JL; Saibil HR; Dobson CM
    J Mol Biol; 2001 Aug; 311(2):325-40. PubMed ID: 11478864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH.
    Souillac PO; Uversky VN; Millett IS; Khurana R; Doniach S; Fink AL
    J Biol Chem; 2002 Apr; 277(15):12657-65. PubMed ID: 11815605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI.
    Nawata M; Tsutsumi H; Kobayashi Y; Unzai S; Mine S; Nakamura T; Uegaki K; Kamikubo H; Kataoka M; Hamada D
    FEBS J; 2017 Sep; 284(18):3114-3127. PubMed ID: 28736891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN.
    Souillac PO; Uversky VN; Fink AL
    Biochemistry; 2003 Jul; 42(26):8094-104. PubMed ID: 12834361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The folding pathway of the antibody V(L) domain.
    Simpson ER; Herold EM; Buchner J
    J Mol Biol; 2009 Oct; 392(5):1326-38. PubMed ID: 19647749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid fibril formation of the mouse V(L) domain at acidic pH.
    Martsev SP; Dubnovitsky AP; Vlasov AP; Hoshino M; Hasegawa K; Naiki H; Goto Y
    Biochemistry; 2002 Mar; 41(10):3389-95. PubMed ID: 11876647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variable-domain SMA.
    Meng X; Fink AL; Uversky VN
    J Mol Biol; 2008 Sep; 381(4):989-99. PubMed ID: 18619464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?
    Morgan GJ; Usher GA; Kelly JW
    Biochemistry; 2017 Dec; 56(50):6597-6614. PubMed ID: 29200282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid fibril formation by an SH3 domain.
    Guijarro JI; Sunde M; Jones JA; Campbell ID; Dobson CM
    Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4224-8. PubMed ID: 9539718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro.
    McParland VJ; Kad NM; Kalverda AP; Brown A; Kirwin-Jones P; Hunter MG; Sunde M; Radford SE
    Biochemistry; 2000 Aug; 39(30):8735-46. PubMed ID: 10913285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
    Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
    Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Existence of different structural intermediates on the fibrillation pathway of human serum albumin.
    Juárez J; Taboada P; Mosquera V
    Biophys J; 2009 Mar; 96(6):2353-70. PubMed ID: 19289061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localized conformational changes trigger the pH-induced fibrillogenesis of an amyloidogenic λ light chain protein.
    Velázquez-López I; Valdés-García G; Romero Romero S; Maya Martínez R; Leal-Cervantes AI; Costas M; Sánchez-López R; Amero C; Pastor N; Fernández Velasco DA
    Biochim Biophys Acta Gen Subj; 2018 Jul; 1862(7):1656-1666. PubMed ID: 29669263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells.
    Arosio P; Owczarz M; Müller-Späth T; Rognoni P; Beeg M; Wu H; Salmona M; Morbidelli M
    PLoS One; 2012; 7(3):e33372. PubMed ID: 22432016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.